DCF — UT MD ANDERSON CANCER CENTER
Enterprise Value: $-1.5B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-1.5B
Enterprise Value
$-601.3M
PV of Cash Flows
$-859.7M
PV of Terminal Value
$-1.4B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $5.0B | $-15.2M | -0.0% | $-228.8M | $-208.0M |
| Year 2 | $5.2B | $36.4M | 1.0% | $-183.7M | $-151.8M |
| Year 3 | $5.4B | $91.0M | 2.0% | $-135.7M | $-101.9M |
| Year 4 | $5.5B | $121.3M | 2.0% | $-112.1M | $-76.6M |
| Year 5 | $5.7B | $139.2M | 2.0% | $-101.3M | $-62.9M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-1.5B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$4.9B
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.008003474862671346
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5